ZYUS Life Sciences Statistics
ZYUS Life Sciences (ZYUS) Stock Statistics & Valuation Metrics
Total Valuation
ZYUS Life Sciences has a market cap or net worth of CAD 31.00M. The enterprise value is CAD 67.01M.
- Market Cap
- CAD 31.00M
- Enterprise Value
- CAD 67.01M
Share Statistics
ZYUS Life Sciences has 80,522,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 80,522,810
- Owned by Insiders
- 93.88%
- Owned by Institutions
- ―
Financial Efficiency
ZYUS Life Sciences’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- ―
- Profits Per Employee
- 7,813.418
- Employee Count
- 55
- Asset Turnover
- ―
- Inventory Turnover
- ―
Income Statement
In the last 12 months, ZYUS Life Sciences had revenue of ― and earned 429.74K in profits. Earnings per share was ―.
- Revenue
- ―
- Gross Profit
- -1,012
- Operating Income
- -294.26K
- Pretax Income
- ―
- Net Income
- 429.74K
- EBITDA
- -294.26K
- Earnings Per Share (EPS)
- ―
Stock Price Statistics
- Beta
- 0.36
- 52-Week Price Change
- -46.38%
- 50-Day Moving Average
- 0.48
- 200-Day Moving Average
- 0.52
- Relative Strength Index (RSI)
- 40.12
- Average Volume (3m)
- 15.63K
Important Dates
ZYUS Life Sciences upcoming earnings date is Nov 26, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 27, 2026
- Next Earnings Date
- Nov 26, 2026
- Ex-Dividend Date
- ―
Balance Sheet
ZYUS Life Sciences has ― in cash and marketable securities with CAD 0.00 in debt, giving a net cash position of ― billion.
- Cash & Marketable Securities
- ―
- Total Debt
- CAD 0.00
- Net Cash
- ―
- Net Cash Per Share
- ―
- Tangible Book Value Per Share
- ―
Analyst Forecast
The average price target for ZYUS Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -22.57%
- EPS Growth Forecast
- 46.77%

